Apyx Medical Co. (NASDAQ:APYX) Short Interest Update

Apyx Medical Co. (NASDAQ:APYX) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 140,500 shares, a decline of 39.0% from the October 31st total of 230,300 shares. Based on an average daily volume of 42,400 shares, the days-to-cover ratio is presently 3.3 days. Currently, 0.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC bought a new position in shares of Apyx Medical during the 2nd quarter valued at $101,000. Rathbones Group PLC grew its stake in shares of Apyx Medical by 148.0% during the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after buying an additional 150,000 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Apyx Medical by 3.9% in the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after buying an additional 12,180 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of Apyx Medical by 2.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock valued at $685,000 after acquiring an additional 14,481 shares during the last quarter. Finally, Royce & Associates LP lifted its stake in shares of Apyx Medical by 3.4% in the 3rd quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock valued at $3,202,000 after acquiring an additional 85,267 shares during the last quarter. 55.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on APYX shares. JMP Securities reissued a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th. BTIG Research initiated coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They issued a “neutral” rating for the company. Finally, Craig Hallum upgraded shares of Apyx Medical to a “strong-buy” rating in a research note on Thursday, October 24th.

Apyx Medical Price Performance

Apyx Medical stock opened at $1.69 on Thursday. The stock has a market cap of $63.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.21. The company has a quick ratio of 4.52, a current ratio of 5.46 and a debt-to-equity ratio of 3.03. The business has a 50-day simple moving average of $1.24 and a 200 day simple moving average of $1.32. Apyx Medical has a 52 week low of $0.97 and a 52 week high of $3.26.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue of $11.49 million for the quarter, compared to the consensus estimate of $11.66 million. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. During the same quarter last year, the business posted ($0.13) earnings per share. On average, research analysts forecast that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.